News
ANI Pharmaceuticals has commenced a Phase IV trial to compare two dosage levels of Purified Cortrophin Gel for acute gout ...
The CBD-based cream reduced UVA damage, preventing nuclear and mitochondrial DNA mutations associated with skin ageing and ...
Medicus Pharma has announced the commencement of the Phase II SKNJCT-004 trial for non-invasive treatment of BCC of the skin.
Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...
At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...
Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.
Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.
Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.
Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...
AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.
KaliVir Immunotherapeutics has concluded the first cohort in the Phase I/Ib STEALTH-001 trial evaluating VET3-TGI for ...
The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results